AI Earnings Predictions for McKesson Corporation (MCK)

EX-99.1

6 mck_exhibit991x9302026.htm

EX-99.1

Document

Exhibit 99.1

McKESSON REPORTS FISCAL 2027 SECOND QUARTER RESULTS

AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE

IRVING, Texas, November 4, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the second quarter ended September 30, 2026.

Second Quarter Highlights:

•Consolidated revenues of $111.0 billion increased 8%.

•Earnings per diluted share of $10.44 increased $1.52.

•Adjusted Earnings per Diluted Share of $11.68 increased 18%.

•Generated $3.1 billion of cash flow from operations and $2.9 billion of Free Cash Flow.

Fiscal 2027 Full Year Outlook:

•Raised Adjusted Earnings per Diluted Share guidance range to $45.60 to $46.40, from the previous range of $44.20 to $45.00.

•Fiscal 2027 Adjusted Earnings per Diluted Share guidance range indicates 17% to 19% growth compared to the prior year.

•The Company does not forecast GAAP earnings per diluted share1.

“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise,” said Brian Tyler, chair and chief executive officer. “We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline. We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders. As we close out a strong first half of our fiscal year, I want to thank Team McKesson for their unwavering commitment to excellence and for the impact they make across healthcare every day.”

Fiscal 2027 Second Quarter Result Summary

Second QuarterYear-to-Date

($ in millions, except per share amounts)FY27FY26% ChangeFY27FY26% Change

Revenues$110,957 $103,150 8 $216,337 $200,977 8

Net income attributable to McKesson Corporation1,218 1,110 10 1,832 1,894 (3)

Adjusted Earnings2 1,363 1,227 11 2,546 2,264 12

Earnings per diluted common share attributable to McKesson Corporation10.44 8.92 17 15.53 15.16 2

Adjusted Earnings per Diluted Share2 11.68 9.86 18 21.59 18.12 19

1See below under "Fiscal 2027 Outlook" for full explanation

2Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules

Second quarter revenues were $111.0 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes and distribution of specialty products, partially offset by lower contributions from branded pharmaceuticals.

Second quarter earnings per diluted share was $10.44 compared to $8.92 a year ago, an increase of $1.52.

Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86 a year ago, an increase of 18%, driven by strong operational growth across the North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments, and a lower share count.

During the three months ended September 30, 2026, McKesson generated cash from operations of $3.1 billion, and invested $123 million in capital expenditures, resulting in Free Cash Flow of $2.9 billion. During the first six months of the fiscal year, McKesson generated cash from operations of $2.9 billion, and invested $275 million in capital expenditures, resulting in Free Cash Flow of $2.6 billion.

For the first six months of the fiscal year, McKesson returned $3.6 billion of cash to shareholders, which included $3.4 billion of common stock repurchases and $198 million of dividend payments.

Business Highlights

•McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032.

•On October 5, 2026, McKesson signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health, Inc. This transaction aligns with McKesson’s strategy in supporting the delivery of complex specialty therapies and expanding patient access through community-based care. The transaction is subject to customary closing conditions, including approval by Option Care Health’s stockholders and the receipt of required regulatory approvals.

•On November 2, 2026, McKesson completed the acquisition of Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization service. This acquisition represents a meaningful milestone in advancing its strategy in oncology, multispecialty, and biopharma services.

•On November 2, 2026, PRISM Vision Group expanded its network with the addition of Spectrum Vision Partners, adding more than 150 providers and bringing its total provider network to more than 350.

North American Pharmaceutical Segment

•Revenues we

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786388379.cf83e35a

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99.1

6 mck_exhibit991x3312026.htm

EX-99.1

Document

Exhibit 99.1

McKESSON REPORTS FISCAL 2026 FOURTH QUARTER AND FULL YEAR RESULTS, PROVIDES FISCAL 2027 GUIDANCE,

AND REAFFIRMS LONG-TERM FINANCIAL GROWTH TARGETS

IRVING, Texas, May 7, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2026.

Fourth Quarter Highlights:

•Consolidated revenues of $96.3 billion increased 6%.

•Earnings per diluted share of $13.71 increased $3.70.

•Adjusted Earnings per Diluted Share of $11.69 increased 16%.

•McKesson entered into a $2.25 billion accelerated share repurchase program.

•McKesson's Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $7.7 billion as of April 2026.

Full Year Highlights:

•Consolidated revenues of $403.4 billion increased 12%.

•Earnings per diluted share of $38.38 increased $12.66.

•Adjusted Earnings per Diluted Share of $39.11 increased 18%, above previously communicated long-range growth targets.

•Cash flow from operations of $6.2 billion and Free Cash Flow of $5.4 billion.

Outlook:

•Establishing fiscal 2027 Adjusted Earnings per Diluted Share guidance range of $43.80 to $44.60, which indicates 12% to 14% forecasted growth compared to the prior year.

•Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%.

•The Company does not forecast GAAP earnings per diluted share1.

"McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise," said Brian Tyler, chief executive officer. "We delivered significant progress - expanding specialty provider support, accelerating patient access through our scaled and integrated biopharma support services, and continuing to optimize our portfolio through the divestiture of Europe and the planned separation of our Medical-Surgical business. These accomplishments are a direct result of the talent and operational excellence of our employees, and I want to thank Team McKesson for their continued dedication throughout the year."

"Looking ahead to fiscal 2027, we are well-positioned to build upon this momentum," said Mr. Tyler. "We remain committed to executing with discipline across the portfolio, investing in high-growth and high-margin areas in Oncology and Biopharma Services. By combining our operating execution with a more focused and optimized portfolio, we will continue to deliver sustainable growth and create long-term value for our shareholders."

1 See below under "Fiscal 2027 Outlook" for full explanation

Fiscal 2026 Fourth Quarter and Full Year Result Summary

Fourth QuarterFull Year

($ in millions, except per share amounts)FY26FY25ChangeFY26FY25Change

Revenues$96,295 $90,823 6 %$403,430 $359,051 12 %

Net income attributable to McKesson Corporation1,682 1,260 33 4,762 3,295 45

Adjusted Earnings2 1,434 1,274 13 4,853 4,234 15

Earnings per diluted common share attributable to McKesson Corporation13.71 10.01 37 38.38 25.72 49

Adjusted Earnings per Diluted Share2 11.69 10.12 16 39.11 33.05 18

2 Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules

Fourth quarter revenues were $96.3 billion, an increase of 6% from a year ago, driven by growth in the distribution of oncology and multispecialty products, including contributions from acquisitions in the Oncology & Multispecialty segment, and growth in the North American Pharmaceutical segment due to increased prescription volumes, partially offset by lower contributions from branded pharmaceuticals.

Fourth quarter earnings per diluted share was $13.71 compared to $10.01 a year ago, an increase of $3.70. Full year earnings per diluted share was $38.38 compared to $25.72 a year ago, an increase of $12.66.

Fourth quarter Adjusted Earnings per Diluted Share was $11.69 compared to $10.12 a year ago, an increase of 16%, driven by strong operational growth, including contributions from acquisitions in the Oncology & Multispecialty segment, a lower share count, and a lower tax rate. Full year Adjusted Earnings per Diluted Share was $39.11 compared to $33.05 a year ago, an increase of 18%, driven by strong operational growth across the business and a lower share count.

During the three months ended March 31, 2026, McKesson generated cash flow from operations of $3.4 billion, and invested $185 million in capital expenditures, resulting in Free Cash Flow of $3.2 billion. During the fiscal year, McKesson generated cash from operations of $6.2 billion, and invested $745 million in capital expenditures, resulting in Free Cash